IRulya Therapeutics Presents LAM-001 Phase 2a Data in Pulmonary Hypertension

• IRulya Therapeutics expects Phase 2 data for inhaled rapamycin LAM-001 in bronchiolitis obliterans syndrome in the first quarter of 2027.
• The fully enrolled, 19-patient trial evaluates LAM-001 against placebo in patients following double-lung transplantation.
• An ongoing 75-patient Phase 2b trial in pulmonary hypertension associated with interstitial lung disease has data anticipated in the first quarter of 2028.
• A Phase 2 sarcoidosis-associated pulmonary hypertension trial is expected to start in the fourth quarter of 2026; data are anticipated in late 2028.
• An oversubscribed financing raised $115 million upfront in May 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRulya Therapeutics Inc. published the original content used to generate this news brief on October 16, 2026, and is solely responsible for the information contained therein.